Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial

WG, FB, WF, LL, and XK were instrumental in the design of the trial and provided essential administrative support. WF, FB, JC, CJ, ZX, WY, YH, DY, MS, TW, XY, RZ, KK, KW, ZW, WL, ZZ, HZ, QG, XW, LH, XZ, WS, LZ, JY, MW, WH, and ZL played key roles in the collection of materials and patient data. WF and BZ were actively involved in both data collection and analysis. BZ conducted the data analysis. FB, LL, and WG contributed significantly to the interpretation of the data.

留言 (0)

沒有登入
gif